Table 2.
Treatment
| Treatment | Overall | FL | DLBCL | CLL | MCL | MH | AML |
|---|---|---|---|---|---|---|---|
| Stage | |||||||
| Binet B | 3 | 3 | |||||
| II | 2 | 1 | 0 | 0 | 1 | ||
| III | 6 | 3 | 1 | 2 | 0 | ||
| IV | 5 | 2 | 3 | 0 | 0 | ||
| Chemotherapy | |||||||
| R-CHOP | 4 | 1 | 3 | 0 | 0 | 0 | 0 |
| R-mini-CHOP | 3 | 1 | 1 | 0 | 1 | 0 | 0 |
| Ibrutinib | 2 | 0 | 0 | 2 | 0 | 0 | 0 |
| Rituximab | |||||||
| Bendamustin | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| VXLD | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Obinutuzumab | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Rituximab | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Rituximab, HD-MTX, Ifosfamid | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| BEACOPPesc | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Stem cell transplantation | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Radiation therapy | 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Conservative treatment | |||||||
| MCT diet | 10 (58.8%) | 3 | 4 | 1 | 2 | 0 | 0 |
| Parenteral nutrition | 4 (23.5%) | 2 | 0 | 1 | 0 | 1 | 0 |
| both | 3 (17.6%) | 1 | 0 | 1 | 0 | 0 | 1 |